share_log

On April 3, Iterum Therapeutics Received Letter From Nasdaq Indicating That It Is Not In Compliance With Nasdaq Listing Rule

Benzinga ·  Apr 5 16:36
On April 3, Iterum Therapeutics Received Letter From Nasdaq Indicating That It Is Not In Compliance With Nasdaq Listing Rule
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment